• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

髓源性抑制细胞(MDSCs)在移植物抗宿主病(GVHD)中的作用

The Role of Myeloid-Derived Suppressor Cells (MDSCs) in Graft-versus-Host Disease (GVHD).

作者信息

Demosthenous Christos, Sakellari Ioanna, Douka Vassiliki, Papayanni Penelope Georgia, Anagnostopoulos Achilles, Gavriilaki Eleni

机构信息

Hematology Department-BMT Unit, G Papanicolaou Hospital, 57010 Thessaloniki, Greece.

出版信息

J Clin Med. 2021 May 11;10(10):2050. doi: 10.3390/jcm10102050.

DOI:10.3390/jcm10102050
PMID:34064671
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8150814/
Abstract

BACKGROUND

Myeloid-derived suppressor cells (MDSCs) are implicated in the complex interplay involving graft-versus-leukemia (GVL) effects and graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HCT) in hematologic malignancies.

METHODS

A review of literature through PubMed was undertaken to summarize the published evidence on the pathophysiology and clinical implications of MDSCs in allo-HCT. Literature sources published in English since 1978 were searched, using the terms Natural Suppressor (NS) cells, MDSCs, GVHD, and allo-HCT.

RESULTS

In vivo studies demonstrated that MDSCs derived from mobilization protocols could strongly suppress allo-responses mediated by T cells and enhance T-Reg activity, thus inhibiting GVHD toxicity. However, the influence of MDSCs on the GVL effect is not fully defined.

CONCLUSIONS

The induction or maintenance of MDSC suppressive function would be advantageous in suppressing inflammation associated with GVHD. Pathways involved in MDSC metabolism and the inflammasome signaling are a promising field of study to elucidate the function of MDSCs in the pathogenesis of GVHD and translate these findings to a clinical setting.

摘要

背景

髓系来源的抑制性细胞(MDSCs)参与了血液系统恶性肿瘤异基因造血干细胞移植(allo-HCT)后移植物抗白血病(GVL)效应和移植物抗宿主病(GVHD)的复杂相互作用。

方法

通过PubMed对文献进行综述,以总结已发表的关于MDSCs在allo-HCT中的病理生理学和临床意义的证据。检索了自1978年以来以英文发表的文献来源,使用的检索词为自然抑制(NS)细胞、MDSCs、GVHD和allo-HCT。

结果

体内研究表明,动员方案产生的MDSCs可强烈抑制T细胞介导的同种异体反应并增强调节性T细胞(T-Reg)活性,从而抑制GVHD毒性。然而,MDSCs对GVL效应的影响尚未完全明确。

结论

诱导或维持MDSC的抑制功能在抑制与GVHD相关的炎症方面将具有优势。参与MDSC代谢和炎性小体信号传导的途径是一个有前景的研究领域,有助于阐明MDSCs在GVHD发病机制中的功能,并将这些发现转化到临床应用中。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b501/8150814/54774737f2de/jcm-10-02050-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b501/8150814/54774737f2de/jcm-10-02050-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b501/8150814/54774737f2de/jcm-10-02050-g001.jpg

相似文献

1
The Role of Myeloid-Derived Suppressor Cells (MDSCs) in Graft-versus-Host Disease (GVHD).髓源性抑制细胞(MDSCs)在移植物抗宿主病(GVHD)中的作用
J Clin Med. 2021 May 11;10(10):2050. doi: 10.3390/jcm10102050.
2
The mechanistic study behind suppression of GVHD while retaining GVL activities by myeloid-derived suppressor cells.髓系来源的抑制细胞在抑制移植物抗宿主病的同时保留移植物抗肿瘤活性的机制研究。
Leukemia. 2019 Aug;33(8):2078-2089. doi: 10.1038/s41375-019-0394-z. Epub 2019 Feb 8.
3
Umbilical cord blood-derived mesenchymal stromal cells promote myeloid-derived suppressor cell proliferation by secreting HLA-G to reduce acute graft-versus-host disease after hematopoietic stem cell transplantation.脐带血来源的间充质基质细胞通过分泌 HLA-G 促进髓源性抑制细胞增殖,从而降低造血干细胞移植后急性移植物抗宿主病的发生。
Cytotherapy. 2020 Dec;22(12):718-733. doi: 10.1016/j.jcyt.2020.07.008. Epub 2020 Aug 15.
4
Ikaros deficiency in host hematopoietic cells separates GVL from GVHD after experimental allogeneic hematopoietic cell transplantation.实验性异基因造血细胞移植后,宿主造血细胞中Ikaros缺乏可将移植物抗白血病效应与移植物抗宿主病区分开来。
Oncoimmunology. 2015 Apr 1;4(7):e1016699. doi: 10.1080/2162402X.2015.1016699. eCollection 2015 Jul.
5
Graft monocytic myeloid-derived suppressor cell content predicts the risk of acute graft-versus-host disease after allogeneic transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood stem cells.移植物中单核细胞来源的髓系抑制细胞含量可预测粒细胞集落刺激因子动员的外周血干细胞异体移植后急性移植物抗宿主病的风险。
Biol Blood Marrow Transplant. 2014 Dec;20(12):2049-55. doi: 10.1016/j.bbmt.2014.09.011. Epub 2014 Sep 20.
6
Myeloid-Derived Suppressor Cells in the Context of Allogeneic Hematopoietic Stem Cell Transplantation.异基因造血干细胞移植背景下的髓源性抑制细胞。
Front Immunol. 2020 May 22;11:989. doi: 10.3389/fimmu.2020.00989. eCollection 2020.
7
GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells.移植物抗宿主病相关的、炎性小体介导的过继转移骨髓来源抑制细胞功能丧失。
Blood. 2015 Sep 24;126(13):1621-8. doi: 10.1182/blood-2015-03-634691. Epub 2015 Aug 11.
8
Early myeloid-derived suppressor cells (HLA-DR/CD33CD16) expanded by granulocyte colony-stimulating factor prevent acute graft-versus-host disease (GVHD) in humanized mouse and might contribute to lower GVHD in patients post allo-HSCT.早期髓系来源的抑制细胞(HLA-DR/CD33CD16)经粒细胞集落刺激因子扩增可预防人源化小鼠的急性移植物抗宿主病(GVHD),并可能降低 allo-HSCT 后患者的 GVHD 发生率。
J Hematol Oncol. 2019 Mar 18;12(1):31. doi: 10.1186/s13045-019-0710-0.
9
Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.对于急性白血病患者,GVHD 无复发生存率优于 G-BM 到 G-PBSC 移植物,这与同种异体移植中更高的髓系抑制细胞含量有关。
J Hematol Oncol. 2017 Jul 4;10(1):135. doi: 10.1186/s13045-017-0503-2.
10
Predictive Role of Circulating Immune Cell Subtypes Early after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia.急性白血病患者异基因造血干细胞移植后早期循环免疫细胞亚群的预测作用
Int J Stem Cells. 2018 Dec 31;12(1):73-83. doi: 10.15283/ijsc18094.

引用本文的文献

1
Interleukin Networks in GVHD: Mechanistic Crosstalk, Therapeutic Targeting, and Emerging Paradigms.移植物抗宿主病中的白细胞介素网络:机制性相互作用、治疗靶点及新出现的模式
Int J Mol Sci. 2025 Sep 4;26(17):8620. doi: 10.3390/ijms26178620.
2
Cellular therapies for the prevention and treatment of acute graft-versus-host disease.用于预防和治疗急性移植物抗宿主病的细胞疗法。
Stem Cells. 2025 May 27;43(6). doi: 10.1093/stmcls/sxaf009.
3
Graft-Versus-Host Disease Mouse Models: A Clinical-Translational Perspective.移植物抗宿主病小鼠模型:临床转化视角

本文引用的文献

1
Adoptive Transfer of Regulatory Immune Cells in Organ Transplantation.移植中调节性免疫细胞的过继转移
Front Immunol. 2021 Mar 2;12:631365. doi: 10.3389/fimmu.2021.631365. eCollection 2021.
2
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity.在髓系细胞多样性不断增加的时代中的髓源性抑制细胞。
Nat Rev Immunol. 2021 Aug;21(8):485-498. doi: 10.1038/s41577-020-00490-y. Epub 2021 Feb 1.
3
Myeloid-derived suppressor cells therapy enhance immunoregulatory properties in acute graft versus host disease with combination of regulatory T cells.
Methods Mol Biol. 2025;2907:1-56. doi: 10.1007/978-1-0716-4430-0_1.
4
Myeloid-derived suppressor cells exhibit distinct characteristics in bone marrow and blood of individuals with diffuse large B-cell lymphoma.髓源性抑制细胞在弥漫性大B细胞淋巴瘤患者的骨髓和血液中表现出不同的特征。
Front Med (Lausanne). 2025 Jan 29;11:1515097. doi: 10.3389/fmed.2024.1515097. eCollection 2024.
5
Pathophysiology and preclinical relevance of experimental graft-versus-host disease in humanized mice.人源化小鼠实验性移植物抗宿主病的病理生理学及临床前相关性
Biomark Res. 2024 Nov 14;12(1):139. doi: 10.1186/s40364-024-00684-9.
6
Decreased circulating myeloid-derived suppressor cell count at the engraftment is one of the risk factors for multiple myeloma relapse after autologous hematopoietic stem cell transplantation.移植时循环髓系来源抑制细胞计数降低是自体造血干细胞移植后多发性骨髓瘤复发的危险因素之一。
Heliyon. 2024 Feb 16;10(5):e26362. doi: 10.1016/j.heliyon.2024.e26362. eCollection 2024 Mar 15.
7
Perspectives for the Use of Umbilical Cord Blood in Transplantation and Beyond: Initiatives for an Advanced and Sustainable Public Banking Program in Greece.脐带血在移植及其他领域的应用前景:希腊先进且可持续公共库项目的倡议
J Clin Med. 2024 Feb 18;13(4):1152. doi: 10.3390/jcm13041152.
8
Assessment of monocytic-myeloid-derived suppressive cells (M-MDSC) before and after allogeneic hematopoietic stem cell transplantation in acute leukemia patients.急性白血病患者异基因造血干细胞移植前后单核细胞来源的髓系抑制细胞(M-MDSC)的评估
EJHaem. 2023 Sep 21;4(4):1089-1095. doi: 10.1002/jha2.795. eCollection 2023 Nov.
9
Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy.异基因造血干细胞移植后急性髓系白血病的复发:免疫逃逸机制及目前对治疗的影响。
Mol Cancer. 2023 Nov 11;22(1):180. doi: 10.1186/s12943-023-01889-6.
10
A pan-cancer analysis of SLC1A5 in human cancers.人类癌症中SLC1A5的泛癌分析。
Heliyon. 2023 Jun 23;9(6):e17598. doi: 10.1016/j.heliyon.2023.e17598. eCollection 2023 Jun.
髓源性抑制细胞疗法联合调节性T细胞可增强急性移植物抗宿主病中的免疫调节特性。
J Transl Med. 2020 Dec 14;18(1):483. doi: 10.1186/s12967-020-02657-6.
4
Increased Galectin-9 expression, a prognostic biomarker of aGVHD, regulates the immune response through the Galectin-9 induced MDSC pathway after allogeneic hematopoietic stem cell transplantation.Galectin-9 表达增加是移植物抗宿主病(aGVHD)的预后生物标志物,在异基因造血干细胞移植后,通过 Galectin-9 诱导的髓系来源抑制细胞(MDSC)通路调节免疫反应。
Int Immunopharmacol. 2020 Nov;88:106929. doi: 10.1016/j.intimp.2020.106929. Epub 2020 Sep 1.
5
Rapamycin-based graft-versus-host disease prophylaxis increases the immunosuppressivity of myeloid-derived suppressor cells without affecting T cells and anti-tumor cytotoxicity.雷帕霉素为基础的移植物抗宿主病预防增加了髓源抑制细胞的免疫抑制性,而不影响 T 细胞和抗肿瘤细胞毒性。
Clin Exp Immunol. 2020 Dec;202(3):407-422. doi: 10.1111/cei.13496. Epub 2020 Aug 1.
6
Myeloid-Derived Suppressor Cells in the Context of Allogeneic Hematopoietic Stem Cell Transplantation.异基因造血干细胞移植背景下的髓源性抑制细胞。
Front Immunol. 2020 May 22;11:989. doi: 10.3389/fimmu.2020.00989. eCollection 2020.
7
A New Era in Endothelial Injury Syndromes: Toxicity of CAR-T Cells and the Role of Immunity.内皮损伤综合征的新纪元:嵌合抗原受体 T 细胞的毒性和免疫的作用。
Int J Mol Sci. 2020 May 29;21(11):3886. doi: 10.3390/ijms21113886.
8
The Impact of Antibiotic-Mediated Modification of the Intestinal Microbiome on Outcomes of Allogeneic Hematopoietic Cell Transplantation: Systematic Review and Meta-Analysis.抗生素介导的肠道微生物组改变对异基因造血细胞移植结局的影响:系统评价和荟萃分析。
Biol Blood Marrow Transplant. 2020 Sep;26(9):1738-1746. doi: 10.1016/j.bbmt.2020.05.011. Epub 2020 May 21.
9
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.芦可替尼治疗糖皮质激素难治性急性移植物抗宿主病。
N Engl J Med. 2020 May 7;382(19):1800-1810. doi: 10.1056/NEJMoa1917635. Epub 2020 Apr 22.
10
Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial.芦可替尼治疗激素耐药性急性移植物抗宿主病(REACH1):一项多中心、开放标签的 2 期试验。
Blood. 2020 May 14;135(20):1739-1749. doi: 10.1182/blood.2020004823.